Viracta Therapeutics (VIRX) 10-Q2007 Q2 Quarterly report

Filed: 8 Aug 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ability, absolute, acid, administered, agent, allocation, America, AML, anemia, animal, announced, announcement, API, assessing, attached, attention, biotechnology, bleeding, blockage, blood, bloodstream, bone, breath, broad, bruising, build, calcium, capability, capable, cardiac, carefully, case, causality, cGMP, choose, comibination, commonly, comparison, competitive, complication, concentration, conflicting, contract, contractually, corrected, count, cytarabine, cytotoxic, daily, death, decided, degree, deliver, delivering, demonstrate, demonstrated, depriving, diarrhea, diverted, dose, dosing, efficacy, employ, escalation, exhibit, experienced, explored, extensive, extreme, face, facilitating, failure, fatigue, Fodor, Food, foreign, framework, gastrointestinal, Good, growth, hair, halted, harm, health, healthcare, high, hire, immaterial, impair, implement, impossible, ineffective, infection, infusion, ingredient, Inititative, injury, inspection, instituted, interval, intestinal, introduction, inventory, irrespective, issuer, kidney, kill, language, large, launch, lawsuit, left, leukemia, light, likelihood, Likewise, liquid, liquidity, litigation, liver, low, lymphoid, manner, marrow, met, mild, monitor, mouth, multiple, myeloid, narrow, nausea, necessity, Nexavar, NOL, North, opportunity, pan, part, past, peak, phosphate, Pierce, PK, platelet, potassium, potent, Practice, precise, prevalence, prevent, prevention, prioritize, profit, profitability, profitable, proliferation, promote, pronounced, proper, prove, pursue, QT, QTc, quality, rapidly, reached, recent, recently, receptive, red, regimen, released, remote, rent, repeated, replace, replacement, rhythm, safe, safety, scale, shelf, shortage, show, side, Similarly, single, slightly, space, specific, sponsor, staffing, standard, Stephen, strength, strict, structured, substantive, suggest, suitable, supplier, supply, supplying, suspending, suspension, sustain, sustained, syndrome, taxable, test, testing, therapy, tolerated, toxic, toxicity, tumor, type, typically, unable, unacceptable, unannounced, unconsolidated, undergoing, underwriting, unrelated, unwilling, upside, uric, Valerie, validated, validation, variability, variable, vomiting, white, window, witnessed, Young

Removed: accredited, accrued, approximate, bear, cessation, closed, compared, computation, consideration, credited, detailed, directed, drawdown, effected, federal, granting, immune, Innovation, investor, level, LIBOR, ratably, reimbursed, repaid, repurchase, restated, unvested

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VIRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification of Chief Executive Officer

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Daniel N. Swisher, Jr., Chief Executive Officer of Sunesis Pharmaceuticals, Inc. (the "Company"), hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2007, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 8, 2007		/s/ Daniel N. Swisher, Jr.
		Daniel N. Swisher, Jr. President and Chief Executive Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.